Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Operating Leases (2023 - 2025)

Zenas BioPharma has reported Operating Leases over the past 3 years, most recently at $211000.0 for Q4 2025.

  • Quarterly results put Operating Leases at $211000.0 for Q4 2025, down 3.21% from a year ago — trailing twelve months through Dec 2025 was $211000.0 (down 3.21% YoY), and the annual figure for FY2025 was $211000.0, down 3.21%.
  • Operating Leases for Q4 2025 was $211000.0 at Zenas BioPharma, up from $180000.0 in the prior quarter.
  • Over the last five years, Operating Leases for ZBIO hit a ceiling of $317000.0 in Q1 2025 and a floor of $180000.0 in Q3 2025.
  • Median Operating Leases over the past 3 years was $216500.0 (2024), compared with a mean of $233000.0.
  • Biggest five-year swings in Operating Leases: dropped 15.18% in 2024 and later fell 3.21% in 2025.
  • Zenas BioPharma's Operating Leases stood at $257000.0 in 2023, then dropped by 15.18% to $218000.0 in 2024, then fell by 3.21% to $211000.0 in 2025.
  • The last three reported values for Operating Leases were $211000.0 (Q4 2025), $180000.0 (Q3 2025), and $215000.0 (Q2 2025) per Business Quant data.